Clinical trials: Alzheimer's
Alzheimer's Disease, Frontotemporal Dementia
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease…
- Trial name
- NCT01890343
- Testing
- florbetapir 18F, 18F-FDG
- Where
- United Kingdom
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Mild to Moderate Alzheimer Disease, Cognitive Impairment
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
The primary purpose of this study is to determine the efficacy and safety of Sodium Oligo-mannurarate (GV-971) in 36-week treatment of mild to moderate Alzheimer's disease.
- Trial name
- NCT02293915
- Testing
- Sodium oligo-mannurarate 900mg
- Where
- 16 sites in China
- Volunteers
- 818 people
- Sponsor
- Shanghai Greenvalley Pharmaceutical Co., Ltd.
Alzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
- Trial name
- NCT03671889
- Testing
- Blood Brain Barrier (BBB) Disruption
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- InSightec
Alzheimer Disease
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Trial name
- NCT05295615
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Herrick Medical LLC
Alzheimer Disease
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
A two-year safety study of simufilam (PTI-125) 100 mg oral tablets twice daily for participants of the previous simufilam studies as wells as additional new mild-to-moderate Alzheimer's disease subjects for a total of 200…
- Trial name
- PTI-125 (NCT04388254)
- Testing
- Simufilam 100 mg oral tablet
- Where
- 17 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Cassava Sciences, Inc.
Mild Cognitive Impairment, Alzheimer Disease
Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease
The purpose of this platform study was to evaluate the effect of anti-inflammatory agents on cognition in early Alzheimer's disease.
- Trial name
- NCT04795466
- Testing
- Canakinumab
- Where
- 10 sites in United States, Finland and 2 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Early Alzheimer's Disease
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD).
- Trial name
- NCT07033494
- Testing
- MK-2214
- Where
- 80 sites in United States, Argentina and 9 more
- Volunteers
- 340 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer's Disease
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00093951
- Testing
- SGS742
- Where
- 59 sites in United States
- Volunteers
- 280 people
- Sponsor
- Saegis Pharmaceuticals
Alzheimer's Disease
A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects
The primary objective of this proof of mechanism pilot clinical trial is to determine if the RXR agonist bexarotene acts in humans to alter the CSF levels of apoE and alter the clearance of Amyloid-Beta
- Trial name
- NCT02061878
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ReXceptor, Inc.
Alzheimer's Disease
QTc Study of Rosi XR in Healthy Volunteers
This study is a randomised double blind, parallel group, and will evaluate the effects of repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a population of healthy adult males and females.
- Trial name
- Rosi XR (NCT00884533)
- Testing
- Rosi XR, Moxifloxacin
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer Disease, Cognitive Impairment
The REMIND Study- SPARK Neuro Software Study
The study utilizes investigational software, the SPARK Test, with an FDA-cleared electroencephalography (EEG) amplifier and EEG cap to collect and patient EEG data.
- Trial name
- NCT05406778
- Testing
- SPARK Test
- Where
- 7 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Spark Neuro Inc.
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Chronic Insomnia
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
- Trial name
- NCT00325728
- Testing
- Ramelteon
- Where
- 72 sites in United States
- Volunteers
- 74 people
- Sponsor
- Takeda
Alzheimer Disease
Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease
clinical trial to assess the efficacy of Acetyl-L-carnitine
- Trial name
- NCT02955706
- Testing
- Acetyl-L-Carnitine
- Where
- South Korea
- Volunteers
- 265 people
- Sponsor
- Dong-A ST Co., Ltd.
Alzheimer's Disease
Observational Study on Costs and Caregiver Burden in Alzheimer's Disease
Objective of study is to assess the costs of care, objective and subjective caregiver burden and quality of life in relation to disease severity measured by cognitive function, ADL capabilities and presence of behavioral…
- Trial name
- NCT00698165
- Where
- 82 sites in United States, Spain and 2 more
- Volunteers
- 2,400 people
- Sponsor
- AstraZeneca
Alzheimer's Disease
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163
The purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of BMS-708163 administered as single and multiple doses in Chinese subjects
- Trial name
- NCT01079819
- Testing
- BMS-708163
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease, Cognition Disorder
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856
The multiple ascending dose (MAD) design of the study is based on the aim to study safety, tolerability, PK and pharmacodynamics of selected doses of ACD856 in a limited number of healthy volunteers.
- Trial name
- NCT05077501
- Testing
- ACD856
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AlzeCure Pharma
Healthy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-ascending dose JNJ-54861911 which is currently being developed for the treatment of Alzheimer's disease.
- Trial name
- NCT01887535
- Testing
- JNJ-54861911 3 mg, JNJ-54861911 10 mg, JNJ-54861911 30 mg
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Alzheimer Disease, Mild to Moderate Alzheimer Disease
A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease
This study is evaluating the safety, tolerability, and feasibility of GRF6019, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT03520998
- Testing
- GRF6019
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alkahest, Inc.
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
- Trial name
- NCT02162264
- Testing
- Donepezil Hydrochloride
- Where
- Japan
- Volunteers
- 8,662 people
- Sponsor
- Eisai Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.